Filtered By:
Education: Study
Management: Venture Capital
This page shows you your search results in order of date.
Order by Relevance | Date
Total 8 results found since Jan 2013.
Append Medical Raises $4.35M in Initial Closing of Extended Series A Round
Funds will be used to complete the development of and support the First-in-Human Study of the Appligator for the Prevention of Stroke in Atrial Fibrillation Patients
OR YEHUDA, Israel, July 6, 2023 -- (Healthcare Sales & Marketing Network) -- Append M... Devices, Interventional, Cardiology, Venture Capital Append Medical, Appligator, left atrial appendage, Atrial Fibrillation
Source: HSMN NewsFeed - July 6, 2023 Category: Pharmaceuticals Source Type: news
Elevian Announces $15 Million Equity Financing
Company Expands Leadership Team as it Advances Preclinical Studies of rGDF11 in Stroke and Other Age-Related Diseases
ALLSTON, Mass., Nov. 24, 2020 -- (Healthcare Sales & Marketing Network) -- Elevian, an emerging biotech company developing medicines t... Biopharmaceuticals, Regenerative Medicine, Venture Capital Elevian, age-related disease, GDF11
Source: HSMN NewsFeed - November 24, 2020 Category: Pharmaceuticals Source Type: news
Will Peregrine Data Be the Turning Point for Hypertension Therapy?
Ablative Solutions just made a significant contribution to the resurgence of renal denervation procedures for the treatment of uncontrolled hypertension. The Kalamazoo, MI-based company added to the treatment’s resurgence narrative by unveiling compelling data from the Peregrine Post-Market Clinical Trial.
The data reveal was during a late-breaking session at the 2019 Cardiovascular Research Technologies meeting in Washington D.C. last week.
The Post-Market Study is a European multicenter open-label trial that evaluated the safety and performance of the Peregrine System Infusion Catheter, which has CE mar...
Source: MDDI - March 8, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news
Mitralign raises $10m
Mitralign, which is looking to commercialize its namesake mitral valve treatment and pursue regulatory nods for its Trialign tricuspid valve device, said it raised nearly $10 million.
The $9.8 million funding, of a hoped-for $30.2 million, came from 19 unnamed investors beginning last September, the Tewksbury, Mass.-based company said in a regulatory filing. Mitralign raised a $40 million Series E round in May 2016.
The Mitralign and Trialign devices are designed to use wire and catheters to implant polyester anchors within the annulus of the mitral and tricuspid valves. The anchors are then cinched together to reduce v...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Replacement Heart Valves Wall Street Beat Mitralign Inc. Source Type: news
UCLA helps many to live long and prosper
In Westwood, more than 100 faculty experts from 25 departments have embarked on anall-encompassing push to cut the health and economic impacts of depression in half by the year 2050. The mammoth undertaking will rely on platforms developed by the new Institute for Precision Health, which will harness the power of big data and genomics to move toward individually tailored treatments and health-promotion strategies.On the same 419 acres of land, researchers across the spectrum, from the laboratory bench to the patient bedside, are ushering in a potentially game-changing approach to turning the body ’s immune defenses again...
Source: UCLA Newsroom: Health Sciences - November 9, 2017 Category: Universities & Medical Training Source Type: news
Cheetah Medical raises $12m
Cheetah Medical said today it raised $11.8 million in an expanded Series C funding round as it looks to grow its US footprint.
Financing was provided by existing investors including MVM Life Science Partners, Springfield Investment Management, Fletcher Spaght Ventures, HighCape Partners and Robert Basch Venture Capital, the Newton, Mass.-based company said.
Cheetah Medical provides noninvasive hemodynamic monitoring devices and systems, including its Cheetah Nicom and Starlin SV technologies, which operate around a proprietary algorithm designed to allow physicians to examine a patient’s full hemodynamic profile.
&#...
Source: Mass Device - September 14, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cheetah Medical Source Type: news
4 Key Insights When Raising Money for Your Medtech Startup: Interview with Bruce Shook, CEO of Intact Vascular
Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them!
Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression.
Previously, Shook was Co-founder, Director, President, an...
Source: Mass Device - February 27, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog medsider Source Type: news
HeartWare plunges on uncertainty around its next-gen MVAD pump
Shares of HeartWare International (NSDQ:HTWR) are down some 28% today after the implantable heart pump maker said it can’t predict when it will be able to get its next-generation MVAD program back on line.
Framingham, Mass.-based HeartWare said it expects to post sales of roughly $68 million for the 3 months ended Dec. 31, in line with the consensus forecast on Wall Street for $67.2 million. But the company said its still evaluating date from a CE Mark trial of the MVAD left ventricular assist device that was halted last fall, which it now says show evidence of blood clots in the pump. The incidence of pump thrombo...
Source: Mass Device - January 12, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Wall Street Beat HeartWare International Inc. Source Type: news
